The AMCP Poster Abstract Program provides a forum for authors to share their research with the managed care pharmacy community.
View our Market Insights webinar that features a candid conversation with panelists from AMCP's Market Insights Roundtable on Optimizing the Management of Inherited Blood Disorders, Part 2 - a follow-up program to the 2022 Roundtable.
Health care leaders will need plans for handling new treatments for inherited blood disorders. This might mean changing benefits for treatments to make sure patients can get gene therapy.
Hemophilia, sickle cell disease (SCD), and beta thalassemia (β thal) are inherited blood disorders likely to see multiple significant novel therapies approved in the near future, including the possibility for partial or complete cures with gene therapies.
Hear from a panel of experts discussing how to optimize the management of inherited blood disorders.
